Showing results (1-10 of 407) with videos related to
Sort By:
Pageof 41
Current Opinion in Hematology|November 20, 2023
Pediatric acute myeloid leukemia - novel approachesSeth E Karol, Gwenaelle GueguenSeminars in Hematology|December 1, 2020
Pharmacogenomics and ALL treatment: How to optimize therapySeth E Karol, Jun J YangTherapeutic Advances in Hematology|June 16, 2020
Personalized therapy in pediatric high-risk B-cell acute lymphoblastic leukemiaSeth E Karol, Ching-Hon PuiHaematologica|July 6, 2019
How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?Nicholas J Short, Farhad RavandiThe Lancet. Haematology|April 1, 2023
Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the pastNicholas J Short, Hagop KantarjianCurrent Oncology Reports|February 17, 2017
Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat ItNicholas J Short, Elias JabbourClinical Lymphoma, Myeloma & Leukemia|August 14, 2016
Acute Myeloid Leukemia: Past, Present, and Prospects for the FutureNicholas J Short, Farhad RavandiCurrent Oncology Reports|February 10, 2022
Central Nervous System Involvement in Adults with Acute Leukemia: Diagnosis, Prevention, and ManagementShilpa Paul, Nicholas J ShortAmerican Journal of Hematology|September 25, 2024
Measurable residual disease monitoring in AML: Prospects for therapeutic decision-making and new drug developmentNicholas J Short, Richard DillonThe Lancet. Haematology|June 30, 2022
Choosing between intensive and less intensive front-line treatment approaches for older patients with newly diagnosed acute myeloid leukaemiaNicholas J Short, Hagop KantarjianPageof 41